Central Valley Advisors LLC Takes $956,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Central Valley Advisors LLC acquired a new position in Edwards Lifesciences Co. (NYSE:EWFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 12,538 shares of the medical research company’s stock, valued at approximately $956,000.

Several other institutional investors have also modified their holdings of the company. Turtle Creek Wealth Advisors LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $34,000. Operose Advisors LLC raised its holdings in shares of Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after purchasing an additional 452 shares in the last quarter. SRS Capital Advisors Inc. lifted its stake in Edwards Lifesciences by 292.6% during the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 474 shares during the last quarter. NBC Securities Inc. bought a new stake in Edwards Lifesciences during the third quarter worth approximately $52,000. Finally, ORG Partners LLC acquired a new position in Edwards Lifesciences in the third quarter worth approximately $66,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on EW shares. Citigroup raised their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Wells Fargo & Company upped their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Barclays lifted their target price on shares of Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Finally, Evercore ISI reduced their price target on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $93.88.

View Our Latest Research Report on EW

Edwards Lifesciences Stock Up 0.6 %

Shares of EW traded up $0.56 during midday trading on Tuesday, reaching $90.34. 2,283,863 shares of the stock were exchanged, compared to its average volume of 3,591,521. The company has a market cap of $54.44 billion, a price-to-earnings ratio of 38.71, a P/E/G ratio of 3.26 and a beta of 1.10. The firm has a 50 day simple moving average of $89.95 and a 200-day simple moving average of $81.11. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. Research analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now owns 4,486 shares of the company’s stock, valued at approximately $388,801.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $86.67, for a total value of $2,543,764.50. Following the transaction, the director now directly owns 4,486 shares in the company, valued at approximately $388,801.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bernard J. Zovighian bought 580 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was purchased at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 191,965 shares of company stock valued at $17,013,993. Insiders own 1.27% of the company’s stock.

About Edwards Lifesciences

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.